Stereochemistry & Pharmacological Activity

Stereochemistry — the three-dimensional arrangement of atoms in a molecule — is a fundamental determinant of pharmacological activity. Small differences in spatial arrangement can lead to dramatic differences in receptor affinity, efficacy, metabolic fate, and toxicity. This lesson covers chirality, enantiomers, racemates, the thalidomide case, chiral switches, geometric isomers, and prodrug stereochemistry.

Chirality and Enantiomers

A chiral molecule is one that is non-superimposable on its mirror image. The most common source of chirality is a tetrahedral carbon bearing four different substituents — termed a chiral centre (or stereocentre). The two non-superimposable mirror-image forms are called enantiomers.

Nomenclature

• *R/S system* (CIP rules): Assigns priority to substituents based on atomic number. The molecule is oriented with the lowest-priority group pointing away; if the remaining three decrease in priority clockwise → R (rectus); anticlockwise → S (sinister).
• *d/l or (+)/(−) designation*: Based on optical rotation of plane-polarised light. (+) = dextrorotatory; (−) = laevorotatory. This is experimentally determined and does not correlate with R/S directly.

Enantiomers and Pharmacological Differences

Biological systems (receptors, enzymes, transport proteins) are chiral environments built from L-amino acids and D-sugars. As a result, a drug receptor typically forms a distinct interaction with each enantiomer, leading to:

• Different receptor affinities (potency)
• Different intrinsic efficacies (agonist vs antagonist properties)
• Different metabolic pathways and rates
• Different toxicity profiles

| Drug | Active Enantiomer | Inactive/Harmful Enantiomer | Pharmacological Difference |

|------|------------------|---------------------------|---------------------------|

| Ibuprofen | S-(+)-ibuprofen | R-(−)-ibuprofen | R→S conversion in vivo (chiral inversion); both contribute to activity |

| Ketamine | S-(+)-ketamine (esketamine) | R-(−)-ketamine | S is 4x more potent at NMDA receptor |

| Albuterol (salbutamol) | R-(−)-albuterol (levalbuterol) | S-(+)-albuterol | S enantiomer may worsen airway inflammation |

| Warfarin | S-(−)-warfarin | R-(+)-warfarin | S is 3-5x more potent anticoagulant; S metabolised by CYP2C9 (key DDI site) |

| Bupivacaine | S-(−)-levobupivacaine | R-(+)-bupivacaine | R enantiomer more cardiotoxic |

| Clopidogrel | S-clopidogrel (active metabolite) | Racemic prodrug | Requires CYP2C19 for bioactivation |

---

Racemates

A racemate (racemic mixture) is an equimolar (50:50) mixture of two enantiomers. A racemic drug has no net optical activity because the (+) and (−) forms cancel out. Most early pharmaceutical drugs were racemic — synthesising a single enantiomer was technically difficult and expensive. Many racemic drugs are now known to have one eutomer (active) and one distomer (less active or inactive), or even one eutomer and one toxic enantiomer.

Racemisation

Under certain conditions (temperature, pH extremes, light), a single enantiomer may racemise — converting back to the racemate. This has clinical significance when single-enantiomer drugs are compounded or exposed to inappropriate storage conditions.

---

The Thalidomide Case Study

Thalidomide is the most instructive case in the history of pharmaceutical stereochemistry and drug safety. It was introduced in 1957 as a racemic sedative/antiemetic and was widely used for morning sickness in pregnant women in Europe and Australia (it was not approved in the USA, where FDA medical officer Frances Kelsey withheld approval, largely saving the US from the disaster).

The Tragedy

Between 1957 and 1962, an estimated 10,000–12,000 children were born with phocomelia (severe limb malformation) and other congenital anomalies to mothers who had taken thalidomide during the first trimester. Over 2,000 infants died.

The Stereochemical Explanation

Thalidomide has one chiral centre. The R-(+)-enantiomer has sedative/antiemetic properties and was considered the "therapeutic" form. The S-(−)-enantiomer is teratogenic — it inhibits angiogenesis and IGF-1 and FGF2 signalling critical for limb development.

Critically, even if pure R-thalidomide were administered, in vivo chiral interconversion under physiological pH conditions rapidly generates the S-enantiomer, so administering a single enantiomer cannot avoid teratogenicity.

Legacy and Rehabilitation

Thalidomide is now used (with extremely tight prescribing controls — REMS programme in the USA; named patient basis in NZ) for:

• Erythema nodosum leprosum
• Multiple myeloma (combined with dexamethasone)
• Graft-versus-host disease (investigational)

The thalidomide tragedy led directly to the modern global drug regulatory framework requiring extensive pre-clinical teratogenicity testing, post-market surveillance, and the concept of thalidomide and its analogues (lenalidomide, pomalidomide) being managed under strict REMS/pregnancy prevention programmes.

---

Chiral Switches

A "chiral switch" refers to the development and regulatory approval of a single-enantiomer version of a previously marketed racemate. The commercial rationale includes:

• Improved therapeutic index (fewer adverse effects from removing the distomer)
• New patent protection extending market exclusivity
• Potentially reduced dosing (higher potency of eutomer)

| Racemate | Chiral Switch | Switch Justification |

|----------|--------------|---------------------|

| Omeprazole (Losec) | Esomeprazole (Nexium) | S-enantiomer less variable metabolism (less CYP2C19 conversion to sulfone); greater AUC |

| Citalopram (Cipramil) | Escitalopram (Lexapro/Cipralex) | S-enantiomer is active; R is inactive/antagonistic at allosteric SERT site |

| Albuterol/salbutamol | Levalbuterol/levosalbutamol | R-(−) is the active bronchodilator; claimed reduced adverse effect burden |

| Ofloxacin | Levofloxacin | S-enantiomer 2x more potent; allows halved dose |

| Bupivacaine | Levobupivacaine / Ropivacaine | S-enantiomers less cardiotoxic |

Critics note that not all chiral switches provide clinically meaningful benefit and that the process can be used primarily to extend patent life ("evergreening").

---

Geometric Isomers (Cis/Trans)

Geometric isomerism (also called E/Z isomerism in IUPAC nomenclature) arises from restricted rotation around a double bond or ring system. The spatial arrangement of substituents on either side of the double bond produces cis (same side) and trans (opposite sides) isomers.

Pharmacological Importance

• *Tamoxifen (Z-tamoxifen)*: The Z (cis) isomer is the pharmacologically active selective oestrogen receptor modulator (SERM); the E-isomer has substantially weaker oestrogen antagonism at the breast oestrogen receptor.
• *Cis-platin vs trans-platin*: Cis-diamminedichloroplatinum(II) is a potent chemotherapeutic agent; the trans-isomer is inactive as an anticancer agent (the geometry determines the ability to form intrastrand crosslinks in DNA).
• *Dienestrol*: Synthetic oestrogen; geometric isomers have markedly different oestrogenic potency.
• *Clomiphene*: The zuclomiphene (Z) isomer is strongly oestrogenic; enclomiphene (E) is the active ovulation-inducing component.

---

Prodrug Stereochemistry

A prodrug is a pharmacologically inactive compound that is converted in vivo to an active drug (often by enzymatic hydrolysis, oxidation, or reduction). Stereochemistry is relevant to prodrugs in two ways:

1. The prodrug itself may be chiral and converted with stereospecificity.
2. The active metabolite may be chiral with a preferred configuration.

Examples

• *Enalapril (enalaprilate)*: Enalapril is an ethyl ester prodrug of enalaprilate. Only the (S,S)-enalaprilate enantiomer is the pharmacologically active ACE inhibitor.
• *Clopidogrel*: Racemic thienopyridine prodrug; after CYP2C19 oxidation, the active thiol metabolite is derived predominantly from the S-enantiomer.
• *Oseltamivir (Tamiflu)*: Ethyl ester prodrug of oseltamivir carboxylate; the 3R,4R,5S configuration of the carboxylate is essential for neuraminidase binding.

Design Considerations

Prodrug design must account for stereospecific enzymatic conversion. If the metabolising enzyme (e.g., an esterase) shows strong stereoselectivity, the "wrong" enantiomer of the prodrug may not be efficiently converted, reducing bioavailability of the active form.